BE2013C035I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2013C035I2 BE2013C035I2 BE2013C035C BE2013C035C BE2013C035I2 BE 2013C035 I2 BE2013C035 I2 BE 2013C035I2 BE 2013C035 C BE2013C035 C BE 2013C035C BE 2013C035 C BE2013C035 C BE 2013C035C BE 2013C035 I2 BE2013C035 I2 BE 2013C035I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301129 | 2003-08-05 | ||
| US49545103P | 2003-08-14 | 2003-08-14 | |
| EP04739008A EP1660531A2 (en) | 2003-08-05 | 2004-07-22 | Novel insulin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2013C035I2 true BE2013C035I2 (en) | 2023-12-14 |
Family
ID=34117520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2013C035C BE2013C035I2 (en) | 2003-08-05 | 2013-06-11 | |
| BE2013C038C BE2013C038I2 (en) | 2003-08-05 | 2013-06-19 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2013C038C BE2013C038I2 (en) | 2003-08-05 | 2013-06-19 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7615532B2 (en) |
| EP (3) | EP2107069B1 (en) |
| JP (1) | JP4463814B2 (en) |
| KR (1) | KR101159559B1 (en) |
| AU (2) | AU2004261353B2 (en) |
| BE (2) | BE2013C035I2 (en) |
| BR (1) | BRPI0413276B8 (en) |
| CA (1) | CA2531988C (en) |
| CY (3) | CY1113850T1 (en) |
| FR (1) | FR13C0035I2 (en) |
| HU (1) | HUS1300033I1 (en) |
| IL (1) | IL172980A (en) |
| LU (2) | LU92213I2 (en) |
| MX (1) | MXPA06001283A (en) |
| NO (3) | NO340925B1 (en) |
| PL (1) | PL2107069T3 (en) |
| RU (1) | RU2518460C2 (en) |
| WO (1) | WO2005012347A2 (en) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007520441A (en) * | 2003-07-25 | 2007-07-26 | コンジュシェム，インコーポレイティド | Persistent insulin derivatives and methods thereof |
| EP2107069B1 (en) | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| ES2438145T3 (en) * | 2005-02-02 | 2014-01-16 | Novo Nordisk A/S | New insulin derivatives |
| ES2490243T3 (en) | 2005-02-02 | 2014-09-03 | Novo Nordisk A/S | Insulin derivatives |
| PT1969004E (en) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| WO2007096431A1 (en) * | 2006-02-27 | 2007-08-30 | Novo Nordisk A/S | Insulin derivatives |
| WO2007104736A2 (en) * | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| US8293965B2 (en) | 2006-04-28 | 2012-10-23 | Kimberly-Clark Worldwide, Inc. | Antimicrobial site dressings |
| CN101437849B (en) * | 2006-05-09 | 2015-09-30 | 诺沃-诺迪斯克有限公司 | Insulin derivates |
| WO2007128815A1 (en) | 2006-05-09 | 2007-11-15 | Novo Nordisk A/S | Insulin derivative |
| EP2015770B1 (en) * | 2006-05-09 | 2012-09-26 | Novo Nordisk A/S | Insulin derivative |
| JP5097900B2 (en) * | 2006-06-27 | 2012-12-12 | 独立行政法人物質・材料研究機構 | Method for producing active ester of organic acid or derivative thereof |
| ES2542146T3 (en) * | 2006-07-31 | 2015-07-31 | Novo Nordisk A/S | PEGylated extended insulin. |
| BRPI0717098B8 (en) | 2006-09-22 | 2021-05-25 | Novo Nordisk As | protease-resistant human insulin analogues, pharmaceutical composition and process for their preparation |
| JP5496082B2 (en) | 2007-04-30 | 2014-05-21 | ノボ・ノルデイスク・エー／エス | Method for drying protein composition, dry protein composition, and pharmaceutical composition containing dry protein |
| JP5628026B2 (en) * | 2007-06-01 | 2014-11-19 | ノボ・ノルデイスク・エー／エス | Stable non-aqueous pharmaceutical composition |
| EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| US9034818B2 (en) | 2007-06-13 | 2015-05-19 | Novo Nordisk A/S | Pharmaceutical formulations comprising an insulin derivative |
| US8962794B2 (en) | 2007-08-15 | 2015-02-24 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| CN101784562B (en) | 2007-08-15 | 2016-07-13 | 诺沃-诺迪斯克有限公司 | There is the insulin analog of acyl group and aklylene glycol moiety |
| CN101157725B (en) * | 2007-10-24 | 2012-07-25 | 中国药科大学 | Preparation method of human insulin analogue and usage thereof |
| US8710000B2 (en) | 2007-11-08 | 2014-04-29 | Novo Nordisk A/S | Insulin derivative |
| PL2209800T3 (en) | 2007-11-16 | 2013-12-31 | Novo Nordisk As | Stable pharmaceutical compositions comprising liraglutide and degludec |
| EP2254905B1 (en) | 2008-03-14 | 2016-12-14 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
| BRPI0910348B1 (en) | 2008-03-18 | 2021-06-29 | Novo Nordisk A/S | INSULIN STABILIZED IN ACILLED PROTEASE, PHARMACEUTICAL COMPOSITION INCLUDING IT AND ITS USES |
| EP2340049B1 (en) | 2008-09-12 | 2015-11-11 | Novo Nordisk A/S | Method of acylating a peptide or protein |
| CN102202683A (en) * | 2008-10-30 | 2011-09-28 | 诺沃-诺迪斯克有限公司 | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| JP5599822B2 (en) | 2009-01-23 | 2014-10-01 | ノヴォ ノルディスク アー／エス | FGF21 derivatives having albumin binder ABCDE and their use |
| EP2493919A1 (en) | 2009-10-30 | 2012-09-05 | Novo Nordisk A/S | Derivatives of cgrp |
| CN102753150A (en) * | 2010-01-12 | 2012-10-24 | 诺沃—诺迪斯克有限公司 | Pharmaceutical compositions for oral administration of insulin peptides |
| ES2582590T3 (en) | 2010-02-16 | 2016-09-13 | Novo Nordisk A/S | Purification method |
| CN102812039B (en) | 2010-02-16 | 2016-01-20 | 诺沃—诺迪斯克有限公司 | Conjugated protein |
| CN107029212A (en) | 2010-05-10 | 2017-08-11 | 诺沃—诺迪斯克有限公司 | Method for preparing zinc insulin compound |
| WO2011146972A1 (en) | 2010-05-25 | 2011-12-01 | Monash University | Methods for the synthesis of dicarba bridges in peptides |
| EP2585483A1 (en) | 2010-06-23 | 2013-05-01 | Novo Nordisk A/S | Human insulin containing additional disulfide bonds |
| CN104693302A (en) | 2010-06-23 | 2015-06-10 | 诺沃—诺迪斯克有限公司 | Insulin derivatives containing additional disulfide bonds |
| WO2011161124A1 (en) | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin analogues containing additional disulfide bonds |
| JP2013540771A (en) | 2010-10-15 | 2013-11-07 | ノヴォ ノルディスク アー／エス | Novel N-terminally modified insulin derivative |
| DK2632478T3 (en) * | 2010-10-27 | 2019-10-07 | Novo Nordisk As | TREATMENT OF DIABETES MELITUS USING INSULIN INJECTIONS SUBMITTED AT VARIOUS INJECTION INTERVALS |
| RS59423B1 (en) | 2010-10-27 | 2019-11-29 | Novo Nordisk As | Treating diabetes melitus using insulin injections administered with varying injection intervals |
| JP2013545782A (en) | 2010-12-14 | 2013-12-26 | ノヴォ ノルディスク アー／エス | Fast-acting insulin combined with long-acting insulin |
| JP2014510516A (en) | 2011-02-15 | 2014-05-01 | ノヴォ ノルディスク アー／エス | Long acting IL-1 receptor antagonist |
| BR112013024076A2 (en) * | 2011-03-28 | 2016-12-06 | Novo Nordisk As | glucagon analogs |
| JP6030630B2 (en) | 2011-04-14 | 2016-11-24 | ノヴォ ノルディスク アー／エス | Fatty acylated amino acids for oral peptide delivery |
| JP6058646B2 (en) | 2011-06-15 | 2017-01-11 | ノヴォ ノルディスク アー／エス | Multi-substituted insulin |
| IN2014CN02448A (en) * | 2011-09-23 | 2015-06-19 | Novo Nordisk As | |
| CN103443122B (en) * | 2011-12-15 | 2016-05-11 | 上海恒瑞医药有限公司 | Human insulin analogue and acylated derivatives thereof |
| WO2013093009A1 (en) | 2011-12-21 | 2013-06-27 | Novo Nordisk A/S | N -terminally modified insulin derivatives |
| KR20150002777A (en) | 2012-04-11 | 2015-01-07 | 노보 노르디스크 에이/에스 | Insulin formulations |
| US20160031962A1 (en) * | 2012-04-20 | 2016-02-04 | Kleomenis K. Barlos | Solid phase peptide synthesis of insulin using side chain achored lysine |
| MX363119B (en) | 2012-05-01 | 2019-03-11 | Novo Nordisk As | Pharmaceutical composition. |
| EP2869830B1 (en) | 2012-07-09 | 2016-10-12 | Novo Nordisk A/S | Novel use of insulin derivatives |
| UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| US20150265710A1 (en) | 2012-10-17 | 2015-09-24 | Novo Nordisk A/S | Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery |
| SG11201503526UA (en) | 2012-12-21 | 2015-06-29 | Sanofi Sa | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| US20160296602A1 (en) * | 2013-03-20 | 2016-10-13 | Novo Nordisk A/S | Dosing Regimen |
| KR20160021758A (en) | 2013-04-18 | 2016-02-26 | 노보 노르디스크 에이/에스 | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| ES2676065T3 (en) | 2013-10-07 | 2018-07-16 | Novo Nordisk A/S | New derivative of an insulin analog |
| FR3013049B1 (en) | 2013-11-14 | 2015-11-13 | You-Ping Chan | ANALOGUE OF INSULIN GLARGINE |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| AU2015220909A1 (en) | 2014-02-18 | 2016-07-14 | Novo Nordisk A/S | Stable glucagon analogues and use for treatment of hypoglycaemia |
| AR099569A1 (en) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE |
| TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
| TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
| TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
| AR105284A1 (en) | 2015-07-10 | 2017-09-20 | Sanofi Sa | DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS |
| WO2017032797A1 (en) | 2015-08-25 | 2017-03-02 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| US20190010206A1 (en) | 2015-08-25 | 2019-01-10 | Novo Nordisk A/S | Novel Insulin Derivatives and the Medical Uses Hereof |
| US10815287B2 (en) | 2016-08-02 | 2020-10-27 | Jiangsu Hengrui Medicine Co., Ltd. | Acylated derivative of human insulin or analogue thereof |
| CN110099719A (en) | 2016-11-28 | 2019-08-06 | 诺和诺德股份有限公司 | For improving glycemic control and reducing acute and long term diabetes complications moral paddy insulin |
| US11278596B2 (en) | 2016-11-28 | 2022-03-22 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| WO2018096164A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| IL300839B2 (en) | 2016-12-16 | 2024-04-01 | Novo Nordisk As | Insulin containing pharmaceutical compositions |
| JOP20190273A1 (en) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | Acylated insulin compound |
| KR20200119237A (en) | 2018-02-09 | 2020-10-19 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Codon-optimized precursor gene and signal peptide gene of human insulin analogue |
| TWI742377B (en) | 2018-05-24 | 2021-10-11 | 大陸商江蘇恒瑞醫藥股份有限公司 | A preparation method of precursor of recombinant human insulin or analog thereof |
| US20220023391A1 (en) | 2018-06-26 | 2022-01-27 | Novo Nordisk A/S | System providing dose recommendations for basal insulin titration |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| KR20200017078A (en) | 2018-08-08 | 2020-02-18 | 주식회사 대웅제약 | Long-acting Insulin Analog and Derivatives Thereof |
| KR20200080747A (en) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same |
| KR20200080748A (en) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | A Method for Purifying Proinsulin Using Anion Exchange Chromatography |
| TW202120536A (en) | 2019-07-31 | 2021-06-01 | 美商美國禮來大藥廠 | Relaxin analogs and methods of using the same |
| US20240025957A1 (en) | 2019-12-30 | 2024-01-25 | Gan & Lee Pharmaceuticals Co., Ltd. | Insulin Derivative |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1212679B (en) | 1957-08-03 | 1966-03-17 | Novo Terapeutisk Labor As | Process for the preparation of insulin solutions |
| GB1042194A (en) | 1962-04-30 | 1966-09-14 | Olin Mathieson | Insulin preparations |
| US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3868358A (en) * | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
| GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
| JPS5767548A (en) | 1980-10-14 | 1982-04-24 | Shionogi & Co Ltd | Insulin analog and its preparation |
| FI78616C (en) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Process for preparing an infused stabilized insulin solution having an elevated zinc content |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| US5605884A (en) * | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| JPH01254699A (en) | 1988-04-05 | 1989-10-11 | Kodama Kk | Insulin derivative and use thereof |
| DE3827533A1 (en) * | 1988-08-13 | 1990-02-15 | Hoechst Ag | PHARMACEUTICAL PREPARATION FOR TREATING THE DIABETES MELLITUS |
| AU641631B2 (en) | 1988-12-23 | 1993-09-30 | Novo Nordisk A/S | Human insulin analogues |
| NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
| IT1240314B (en) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | STABILIZED AQUEOUS FORMULATIONS OF SMALL PEPTIDES. |
| DK0506792T3 (en) | 1989-12-21 | 1995-10-09 | Novo Nordisk As | Insulin preparation containing nicotinic acid or nicotinamide |
| DK45590D0 (en) | 1990-02-21 | 1990-02-21 | Novo Nordisk As | |
| JP3193398B2 (en) | 1991-07-23 | 2001-07-30 | サンデン株式会社 | Showcase |
| PT618807E (en) | 1991-12-20 | 2003-03-31 | Novo Nordisk As | STABILIZED PHARMACEUTICAL FORM COMPREHENDING HUMAN GROWTH HORMONE AND HYSTIDINE |
| US6011007A (en) * | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| CA2171424C (en) | 1993-09-17 | 2002-06-04 | Svend Havelund | Acylated insulin |
| US6869930B1 (en) * | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| AU3562195A (en) | 1994-10-04 | 1996-04-26 | Novo Nordisk A/S | Preparations containing aspb28 human insulin and nicotinamide |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5830999A (en) * | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
| US6251856B1 (en) * | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| BR9607647A (en) | 1995-03-17 | 1999-04-06 | Novo Nordisk As | Insulin derivative and pharmaceutical composition and process for the treatment of diabetes in a patient in need of this treatment |
| PT2275119E (en) | 1995-07-27 | 2013-11-21 | Genentech Inc | Stable isotonic lyophilized protein formulation |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| US5898267A (en) * | 1996-04-10 | 1999-04-27 | Mcdermott; Kevin | Parabolic axial lighting device |
| US5866538A (en) * | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5905140A (en) * | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| DE69731105T2 (en) * | 1996-07-11 | 2005-11-17 | Novo Nordisk A/S | METHOD FOR SELECTIVE ACETYLATION |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| DK0821006T3 (en) * | 1996-07-26 | 2004-08-16 | Aventis Pharma Gmbh | Insulin derivatives with increased zinc binding |
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| EP0971729B1 (en) | 1997-03-20 | 2002-07-03 | Novo Nordisk A/S | Therapeutic powder formulation for pulmonary administration, containing crystalline insulin |
| DE69806582T2 (en) | 1997-03-20 | 2003-02-13 | Novo Nordisk As | METHOD FOR PRODUCING A THERAPEUTIC POWDER BY COPRECIPITATING INSULIN AND AN ABSORPTION AMPLIFIER |
| ATE321783T1 (en) * | 1997-03-20 | 2006-04-15 | Novo Nordisk As | ZINC-FREE INSULIN CRYSTALS FOR USE IN MEDICATIONS ADMINISTERED THROUGH THE LUNGS. |
| US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| EP1283051B1 (en) | 1997-06-13 | 2006-06-14 | Eli Lilly And Company | Stable insulin formulations |
| PL340255A1 (en) | 1997-10-24 | 2001-01-29 | Lilly Co Eli | Non-dissolving insulin compositions |
| US20020155994A1 (en) * | 1997-10-24 | 2002-10-24 | Svend Havelund | Aggregates of human insulin derivatives |
| HUP0004096A3 (en) * | 1997-10-24 | 2001-12-28 | Novo Nordisk As | Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof |
| US6451762B1 (en) * | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| ZA989744B (en) * | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| US6531448B1 (en) | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
| WO1999034821A1 (en) * | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
| CN1210058C (en) | 1998-10-16 | 2005-07-13 | 诺沃挪第克公司 | Stable concentrated insulin preparations for pulmonary delivery |
| US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| US6586573B1 (en) * | 1999-02-22 | 2003-07-01 | Baxter International Inc. | Albumin-free Factor VIII formulations |
| CA2370302A1 (en) | 1999-04-27 | 2000-11-02 | Benjamin Lee Hughes | Insulin crystals for pulmonary administration |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| DE10022092A1 (en) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilized protein preparation and process for its preparation |
| US6652886B2 (en) * | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| DE10114178A1 (en) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinc-free and low-zinc insulin preparations with improved stability |
| EP1412384B1 (en) | 2001-06-28 | 2007-12-26 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| MXPA04006084A (en) | 2001-12-20 | 2005-03-31 | Lilly Co Eli | Insulin molecule having protracted time action. |
| AU2003208316A1 (en) * | 2002-03-13 | 2003-09-22 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| EP1506230B1 (en) * | 2002-05-07 | 2011-01-19 | Novo Nordisk A/S | Soluble formulations comprising monomeric insulin and acylated insulin |
| US20050232899A1 (en) * | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| US20040002451A1 (en) * | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
| KR100615389B1 (en) | 2002-08-23 | 2006-08-25 | (주)헬릭서 | Health food comprising the extract of Actinidia arguta and related species for the prevention and improvement of allergic disease and non-allergic inflammatory disease |
| MXPA05004593A (en) | 2002-10-29 | 2005-07-26 | Alza Corp | Stabilized, solid-state polypeptide particles. |
| US20040138099A1 (en) * | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
| RU2358738C2 (en) | 2003-02-07 | 2009-06-20 | Адзиномото Ко., Инк. | Pancreatic diabetes drug |
| JP2007523836A (en) | 2003-02-19 | 2007-08-23 | ノバルティス アクチエンゲゼルシャフト | Glycoprotein antigen SIMA135 expressed in metastatic human tumor cells |
| AU2004216909A1 (en) | 2003-03-04 | 2004-09-16 | The Technology Development Company Ltd. | Delivery system for drug and cell therapy |
| JP4658041B2 (en) | 2003-06-25 | 2011-03-23 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Liquid composition of factor VII polypeptide |
| US20050054818A1 (en) * | 2003-07-02 | 2005-03-10 | Brader Mark Laurence | Crystalline compositions for controlling blood glucose |
| EP2107069B1 (en) | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| SI2107069T1 (en) | 2003-08-05 | 2013-04-30 | Novo Nordisk A/S | Novel insulin derivatives |
| AU2004264282B2 (en) | 2003-08-14 | 2010-10-14 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of Factor VII polypeptides |
| WO2005021022A2 (en) | 2003-09-01 | 2005-03-10 | Novo Nordisk A/S | Stable formulations of peptides |
| ES2229931B1 (en) * | 2003-10-03 | 2006-01-16 | Grifols, S.A. | BILOGICALLY STABLE LIQUID COMPOSITION OF FVIII, FVW OR HUMAN FVIII / FVW COMPLEX. |
| WO2005047508A1 (en) * | 2003-11-14 | 2005-05-26 | Novo Nordisk A/S | Processes for making acylated insulin |
| JP4845741B2 (en) | 2003-12-23 | 2011-12-28 | ファルマシア コーポレーション | Stable growth hormone liquid formulation |
| PT2319500E (en) | 2004-03-12 | 2013-01-23 | Biodel Inc | Rapid acting drug delivery compositions |
| EA012281B1 (en) | 2004-06-01 | 2009-08-28 | Арес Трейдинг С.А. | Method of stabilizing proteins |
| US7632491B2 (en) | 2004-08-12 | 2009-12-15 | Schering Corporation | Stable pegylated interferon formulation |
| PL1778723T3 (en) | 2004-08-17 | 2013-03-29 | Regeneron Pharma | Il-1 antagonist formulations |
| ES2575984T3 (en) | 2004-11-12 | 2016-07-04 | Novo Nordisk A/S | Stable formulations of peptides containing an acylated GLP-1 analogue and a basal insulin |
| US8263551B2 (en) | 2004-11-22 | 2012-09-11 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
| US20060188555A1 (en) | 2005-01-21 | 2006-08-24 | Micheal Cormier | Therapeutic peptide formulations with improved stability |
| ES2438145T3 (en) * | 2005-02-02 | 2014-01-16 | Novo Nordisk A/S | New insulin derivatives |
| PT1969004E (en) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| WO2007096431A1 (en) * | 2006-02-27 | 2007-08-30 | Novo Nordisk A/S | Insulin derivatives |
| US7718609B2 (en) | 2006-04-12 | 2010-05-18 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| EP2015770B1 (en) * | 2006-05-09 | 2012-09-26 | Novo Nordisk A/S | Insulin derivative |
| US9034818B2 (en) * | 2007-06-13 | 2015-05-19 | Novo Nordisk A/S | Pharmaceutical formulations comprising an insulin derivative |
| PL2209800T3 (en) * | 2007-11-16 | 2013-12-31 | Novo Nordisk As | Stable pharmaceutical compositions comprising liraglutide and degludec |
| TWI451876B (en) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | Pegylated insulin lispro compounds |
-
2004
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en active Active
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en active Application Filing
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
- 2004-07-22 PL PL09165072T patent/PL2107069T3/en unknown
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en active Active
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/en active IP Right Grant
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/en active Active
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/en active Protection Beyond IP Right Term
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/en active IP Right Grant
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
-
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/en active Protection Beyond IP Right Term
-
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/en active
-
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en active Active
-
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
-
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/en unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/en unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/en unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/en active Active
- 2013-07-04 CY CY2013027C patent/CY2013027I1/en unknown
- 2013-07-08 CY CY2013029C patent/CY2013029I1/en unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/en unknown
-
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
-
2018
- 2018-01-11 NO NO2018002C patent/NO2018002I2/en unknown
- 2018-01-11 NO NO2018003C patent/NO2018003I1/en unknown